Stratipath, a leader in AI-based precision diagnostic solutions, has announced a collaboration with Roche, the world’s largest biotechnology company and a global leader in in-vitro diagnostics. Through this partnership, Roche gains distribution rights to Stratipath’s AI-driven diagnostic tool, Stratipath Breast. This solution integrates seamlessly with Roche’s navify® Digital Pathology enterprise software, allowing users to perform AI-based prognostic risk profiling for breast cancer directly from the platform.
Stratipath Breast is the first EU regulatory-compliant AI solution designed for breast cancer risk stratification. It uses deep learning to analyze digitized histopathology images, identifying patients at increased risk of disease progression. Unlike conventional molecular tests, this AI-powered approach offers quicker results, reduces dependency on costly molecular testing, and provides crucial insights during the diagnostic process.
Fredrik Wetterhall, CEO and co-founder of Stratipath, highlighted that this collaboration enables global pathology labs to access fast and cost-effective diagnostic insights, further streamlining processes and enhancing patient care. This marks a major step forward in making AI-driven breast cancer diagnostics more accessible worldwide.
For more information visit https://www.stratipath.com/stratipath-and-roche-join-forces-to-help-expand-access-to-ai-powered-precision-diagnostics/
